Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-5.31%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-5.31%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
Nuvectis Pharma Inc fundamental performance
Across Nuvectis Pharma Inc's full reported history, from 2022 to 2025, revenue declined from $ 149K to $ 0.00 and net income went from -$ 18M to -$ 26M. Revenue increased in 0% of the years measured; net income in 25%.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 19.54 | — |
1 Year2025-08-12 | $ 6.82 | 186.51% |
All Time2022-02-04 | $ 3.25 | 6x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | All Time2022-02-04 |
|---|---|---|---|
| Price | $ 19.54 | $ 6.82 | $ 3.25 |
| Return | — | 186.51% | 6x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 27M | $ 22M |
| 2025 | $ 0.00 | -$ 26M | $ 31M |
| 2024 | $ 0.00 | -$ 19M | $ 18M |
| 2023 | $ 0.00 | -$ 22M | $ 19M |
| IPO2022 | $ 149K | -$ 18M | $ 19M |
Explore beyond NVCT
You're looking at Nuvectis Pharma Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
